Tuesday, May 24, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Antibody escape in SARS-CoV-2 Omicron spike protein

by Medical Finance
in Coronavirus
Study: Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein. Image Credit: Naeblys/Shutterstock
9
SHARES
101
VIEWS
Share on FacebookShare on Twitter

In a recent study posted to the bioRxiv* preprint server, researchers examined antibody escape and cross-domain stabilization in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron spike (S) protein.

Study: Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein. Image Credit: Naeblys/Shutterstock
Study: Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein. Image Credit: Naeblys/Shutterstock

The widespread mortality and morbidity caused by rampant coronavirus disease 2019 (COVID-19) transmission have resulted in the emergence of novel SARS-CoV-2 variants of concern (VOCs).

However, the interactions of the new mutations in these VOCs against the Omicron mutational background need extensive research.

About the study

The researchers in the present study characterized the expression, cell receptor affinity, and antibody binding of the SARS-CoV-2 S extracellular domains (ECDs) using cell surface display of the S protein. The team also assessed the impact of all SARS-CoV-2 Omicron mutations on human angiotensin-converting enzyme-2 (hACE-2) binding, the stability of the S protein, and the evasion of monoclonal antibodies (mAbs).

The team used a mammalian cell surface display and compared the expression and antigenicity of the Omicron BA.1 and BA.2 ECDs to other VOCs. They expressed S variants on human embryonic kidney (HEK293T) cells. The S proteins were subsequently immunostained to evaluate the expression, Ab binding, and hACE2 affinity via two-color flow cytometry.

S proteins were first cloned from SARS-CoV-2 Alpha, Beta, Delta, Gamma, and Omicron BA.1 and BA.2 VOCs and Epsilon variant of interest (VOI). The team incorporated the D614G mutation and prefusion stabilizing prolines into the variants to improve surface expression. Each variant was assayed for the expression and the potential of escaping a set of 21 mAbs. These MAbs included nine N-terminal domain (NTDs)-targeting mAbs and 12 neutralizing receptor-binding domain (RBDs)-targeting mAbs. Furthermore, clinically used mAbs like REGN10987 (imdevimab) and REGN10933 (casirivimab), and S309 (sotrovimab) and LY-CoV555 (bamlanivimab) were also included in the study.

The team conducted microneutralization assays on the BA.1 variant along with 10 mAbs, whose neutralization ability against the Wuhan-Hu-1 (WHU1) lineage was known. Furthermore, they examined four NTD-targeting mAbs, each belonging to the four classes of binding mAbs. Subsequently, the team screened the WHU1 S protein variant that contained each mutation found in the BA.1 and BA.2 variants. Also, the impact of RBD substitutions on mAbs was assessed by screening the WHU1 S protein using RBD-targeting mAbs.  

Results

The study results showed that the SARS-CoV-2 Omicron BA.1 and BA.2 variants had increased Ab escape potential compared to other variants. BA.1 effectively evaded a majority of the Abs tested in the present study, including almost all the NTD-targeting mAbs. On the other hand, BA.1 S protein was refractory to several RBD-targeting mAbs and displayed a strong escape potential against all class II binders, half of the total class III binders, and all of the quaternary binders.

Moreover, BA.2 exhibited a substantial level of Ab escape potential; however, it showed susceptibility towards the class I NTD-targeting mAbs and the class III RBD-targeting mAbs. 

In comparison to the WHU1, the BA.1 variant effectively evaded neutralization by class I, class II, and class IV mAbs. This evasion could be attributed to the series of contiguous mutations found on the variant. Interestingly, BA.1 escaped the same Abs as those observed in the mammalian cell surface assay. This indicated that the BA.1 and BA.2 S protein variants were antigenically distinct.

Furthermore, the team observed that the class I mAbs had lowered Ab binding due to the Y145D mutation while the class III and class IV had increased binding that was more susceptible to mutations.

Notably, the BA.2 variant was sensitive toward some of the NTD-binding mAbs. Also, the mutations in BA.2 showed slightly reduced bindings toward class II, III, and IV mAbs. Moreover, with the G142D mutation, BA.2 effectively escaped recognition by Ab at this site.

Among the mAbs tested in this study, a class I mAb, called S2X35, had slightly decreased Ab binding because of the E484A mutation. Furthermore, class II Abs including C002, LY-CoV555, and C144 and the quaternary binder 2-43 were found to be the most influenced by the mutations at E484A and Q493R. The class III mAb REGN10987 also displayed lowered binding due to both N440K and G446S mutations, while C135 was affected by the N440K and Q498R mutations.

Conclusion

Overall, the study findings showed that the continuous emergence of mutations in SARS-CoV-2 variants will further lead to an altered conformational equilibrium, allowing for the formation of more stable and virulent mutations. The researchers believe that the strategy employed in the present study can be extended to develop future therapeutic approaches and vaccine formulations.

*Important notice

bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: T cell apoptosis characterizes severe Covid-19 disease. Image Credit: UGREEN 3S / Shutterstock.com

T-cell apoptosis linked to poor prognosis among COVID-19 patients

by Medical Finance
May 24, 2022
0

There have been multiple factors that have been attributed to disease severity for coronavirus disease (COVID-19), many of which depend...

Study: Comparison of vaccine effectiveness against the Omicron (B.1.1.529) variant in patients receiving haemodialysis. Image Credit: mailsonpignata/Shutterstock

Study explores vaccine effectiveness against the SARS-CoV-2 Omicron variant in patients receiving hemodialysis

by Medical Finance
May 24, 2022
0

Ever since the onset of the coronavirus disease 2019 (COVID-19) pandemic, the causal agent, i.e., severe acute respiratory syndrome coronavirus...

Study: Risk of SARS-CoV-2 reinfection 18 months after primary infection: population-level observational study. Image Credit: grebeshkovmaxim/Shutterstock

SARS-CoV-2 reinfection risk in the population of the Abruzzo Region of Italy

by Medical Finance
May 24, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers evaluated the incidences of severe acute respiratory syndrome coronavirus...

Study: Serological screening in wild ruminants in Germany, 2021/22: No evidence of SARS-CoV-2, bluetongue virus or pestivirus spread but high seroprevalences against Schmallenberg virus. Image Credit:  WildMedia / Shutterstock

No seroprevalence observed against SARS-CoV-2 in wild ruminants in Germany

by Medical Finance
May 24, 2022
0

A team of scientists from Germany has recently conducted a serological screening on wild animals to assess seroprevalence against severe...

Study: Longitudinal Assessment of SARS-CoV-2 Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multi-Cytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity. Image Credit: Merlin74 / Shutterstock.com

Study shows enduring T-cell immunity up to at least 1-year after SARS-CoV-2 infection

by Medical Finance
May 24, 2022
0

The World Health Organization (WHO) has reported over 361 million confirmed coronavirus disease 2019 (COVID-19) cases, of which include over...

Study: Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVD-19 respiratory disease. Image Credit: CROCOTHERY/Shutterstock

Immuno-proteomic profiling suggests aberrant immune cell regulation associated with post-COVD-19 infection

by Medical Finance
May 24, 2022
0

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causal agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic that...

Next Post
Study: Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. Image Credit: Andreas Matzke/Shutterstock

SARS-CoV-2-specific immune responses elicited by inactivated COVID-19 vaccines

Malvern Panalytical expands pharmaceutical drug development solutions through the acquisition of Creoptix

Malvern Panalytical expands pharmaceutical drug development solutions through the acquisition of Creoptix

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Immune and pathophysiologic profiling of antenatal COVID-19 in the GIFT cohort: A Singaporean case-control study. Image Credit: wong sze yuen/Shutterstock
    Durability and neutralization capacity of SARS-CoV-2 specific antibodies in the breastmilk of convalescent COVID-19 mothers
  • Study: Cellulosic copper nanoparticles and a hydrogen peroxide-based disinfectant protect Vero E6 cells against infection by viral pseudotyped particles expressing SARS-CoV-2, SARS-CoV or MERS-CoV Spike protein. Image Credit: Matthias Friel/Shutterstock
    Study indicates combining a hydrogen peroxide-based disinfectant with cellulosic copper nanoparticles lowers human coronaviruses’ infectivity
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply